Research
Hormonal
GLP-1 receptor agonists (e.g., exenatide, liraglutide) reduce food intake and body weight in humans, but their use is limited by side effects like nausea and potential long-term risks.
GLP-1 agonists are effective for weight loss and diabetes management, but they come with side effects like nausea. Long-term safety data is still being gathered. Consult a doctor to weigh the benefits against the side effects.
GoodQualifiesHIGH confidence
GLP-1-based therapies are promising novel treatments for type 2 diabetes... The reported side effects of GLP-1 agonists are nausea and vomiting... long-term outcome data are not yet available.
Why this rating
The paper cites multiple studies showing efficacy, but notes limitations in long-term data.
Source
Obesity and Appetite Control
Keisuke Suzuki et al. · Experimental Diabetes Research · 2012
DOI 10.1155/2012/824305
narrative_reviewCited 226×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Peripheral administration of PYY3-36 reduces food intake and body weight gain in both lean and obese human subjects by acting on hypothalamic Y2 receptors, with sensitivity preserved in obesity unlike leptin.Good
- Ghrelin is the only known orexigenic gut hormone, and its levels are inversely correlated with body mass index, with obese subjects showing a less marked drop in plasma ghrelin after meal ingestion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →